So they have either estrogenrmo testosterone becoming the different and those secondarne becomy characterist. and then aboutbo 50%ut of thosem females get some kind ofat surgery that those are the numbers that from the medicaliteratul literature. and so they re putting these per kids through this permanentwered medicalization pipeline. and they were doing itoi really by bullying parents and then by keeping it a secret, not just from the public, but from attorney general ken paxton and the voters and legislators of the state of texas that keep saying, who are these parents? who are these people?ital and but we reached out to the hospital and they gave us a statement saying our mission is to provide high quality carat for all patients throughoutoundn the policy debate surrounding the gender medicin e, our healthways c care professionals have alwayson and will always continue p to prioritizriore the care of our patients within the bounds of the law. a well, that s a lot of words. what does that tell you ,e that chris ? i mean, it tells me thathat s they re going to try to wait this one out. butt
MedCity News Canvas Medical raises $17M to rebuild health records for primary care Canvas Medical, a startup looking to build electronic medical records and ancillary tools for primary care systems, raised $17 million in funding. Shares0
Canvas Medical, a startup looking to build a new health record system for primary care practices, raised $17 million in funding. The San Francisco-based startup makes software for charting, population health management and billing, intended to replace practices’ current electronic health record systems (EHR). Inspired Capital and IA Ventures led the funding round, with participation from Irongrey and past investors Upfront and iSeed. The company plans to use the funds to build a less fragmented version of health record systems for primary care doctors, especially when it comes to implementing features for value-based care.
Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy.
Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy.
Regeneron, Roche injectable antibody drug shows efficacy in preventing Covid-19 A Regeneron Pharmaceuticals antibody cocktail currently authorized for treating Covid-19 now has additional clinical data showing it reduces the risk of infection spread. The drug developer, along with partner Roche, plan to ask regulators to expand the drug’s authorization to include disease prevention. Shares0 A Covid-19 antibody cocktail developed by Regeneron Pharmaceuticals and Roche has pivotal clinical trial data showing it protected against the spread of infection among people in the same household. The results support use of the drug as a preventative measure in a formulation that’s easier for both physicians and patients.